GLTO

Galecto, Inc. [GLTO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

GLTO Stock Summary

Top 10 Correlated ETFs

GLTO

Top 10 Correlated Stocks

GLTO

In the News

GLTO Financial details

Company Rating
-
Market Cap
18.46M
Income
-37.79M
Revenue
1.2M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
13
Optionable
No
Shortable
Yes
Earnings
26 Apr 2024
P/E
-0.44
Forward P/E
-
PEG
0.11
P/S
-
P/B
0.54
P/C
-
P/FCF
-0.55
Quick Ratio
3.61
Current Ratio
3.75
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.43
EPS next Y
-
EPS next Q
-
EPS this Y
-40.98%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-20%
-
-
-
-
SMA20
-36.76%
SMA50
-51.5%
SMA100
-62.82%
Inst Own
-
Inst Trans
-
ROA
-92%
ROE
-95%
ROC
-1.25%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.5-3.7
52W High
-
52W Low
-
RSI
36.19
Rel Volume
0.08
Avg Volume
231.47K
Volume
19.01K
Perf Week
-28.17%
Perf Month
-47.03%
Perf Quarter
-65.53%
Perf Half Y
-67.6%
-
-
-
-
Beta
1.246
-
-
Volatility
0.21%, 1.02%
Prev Close
4.5%
Price
2.32
Change
-4.53%

Something similar

Top by Market Cap
ABEA.DE
FB2A.DE
AVGO
VTSAX
TL0.DE
Top Correlated ETFs
GRI
HURA.TO
ARKG
URNU.L
261060.KS
Top Correlated Stocks
IFRX
NFE
DTIL
GPRO
ITRM
Similar Market Cap
DEST.L
AXDX
MWB.DE
FLGC
TAVI.L

Company Profile

Healthcare Biotechnology
  • Volume Average 231.47K
  • Market Capitalization 18.46M
  • Employee 13
  • CEO Dr. Hans T. Schambye M.D., Ph.D.
  • Headquarters Boston,MA,US
  • IPO Date 2020-10-29
  • Website https://galecto.com

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.